Guosen Securities: The clinical phase 2 data of Sansheng Pharmaceuticals (01530.HK) 707 combination chemotherapy is announced. Maintains a "outperform the market" rating.

According to the Wise Stock Market APP, Guosen Securities released a research report stating that Sansei Pharmaceuticals (01530.HK) has rapidly promoted its innovative drug clinical trials, completed a major outbound authorization transaction, and maintained steady growth in performance. Considering that the outbound authorization for 707 has been implemented, the bank has raised its profit forecast and expects the company's net profit attributable to the parent company to be 9.955/2.875/3.212 billion yuan in 2025-2027 (previous values were 2.380/2.710/3.070 billion yuan). Sansei Pharmaceuticals' core products are rapidly advancing in global clinical development, and it maintains a "better than market" rating.